Application of selective cyclooxygenase-2 inhibitors in tumor radiotherapy

doi:10.3760/cma.j.issn.1673-422X.2013.11.006

Abstract

Abstract: Cyclooxygenase2 (COX2), the ratelimited enzyme that converts arachidonic acid into prostaglandin, has been found overexpression in many malignant tumors. The overexpression of COX2 plays an important role in tumor genesis and progression and is closely associated with tumor prognosis, so this enzyme has become one of the potential therapeutic targets. Experimental studies reveal that selective COX2 inhibitors can enhance the tumor radiosensitivity through a variety of molecular pathways and have a protective effect for normal tissues. Selective COX2 inhibitors are promising radiotherapy modifiers and the underlying molecular mechanisms still need to be further studied.

Key words: font-family: 'Calibri','sans-serif', mso-ascii-theme-font: minor-latin, mso-fareast-theme-font: minor-fareast, mso-hansi-theme-font: minor-latin, mso-bidi-font-size: 11.0pt, mso-bidi-font-family: 'Times New Roman', mso-bidi-theme-font: minor-bidi, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-fareast-font-family: 宋体">Cyclooxygenase2, Neoplasms, Radiotherapy

LONG Cheng, JIANG Yong-Mei, LI Guo-Quan. Application of selective cyclooxygenase-2 inhibitors in tumor radiotherapy[J]. Journal of International Oncology, 2013, 40(11): 820-823.

References

［1］ Schetter AJ, Heegaard NH, Harris CC, et al. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis， 2010, 31 (1): 37-49. ［2］ Ke HL, Tu HP, Lin HH, et al. Cyclooxygenase-2 (COX-2) upregulation is a prognostic marker for poor clinical outcome of upper tract urothelial cancer. Anticancer Res， 2012,32(9):4111-4116. ［3］ Mestre F, Gutierrez A, Ramos R, et al. Expression of COX2 on ReedSternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD. Blood， 2012, 119(25):6072-6079. ［4］ Wang AH, Tian XY, Yu JJ, et al. Celecoxib radiosensitizes the human cervical cancer HeLa cell line via a mechanism dependent on reduced cyclooxygenase-2 and vascular endothelial growth factor C expression. Int J Med Res, 2012, 40(1):56-66. ［5］ Klenke FM, Abdollahi A, Bischof M, et al. Celecoxib enhances radiation response of secondary bone tumors of a human nonsmall cell lung cancer via antiangiogenesis in vivo. Strahlenther Onkol, 2011, 187(1):45-51. ［6］ Farnebo L, Jerhammar F, Ceder R, et al. Combining factors on protein and gene level to predict radioresponse in head and neck cancer cell lines. J Oral Pathol Med, 2011, 40(10):739-746. ［7］ Akutsu Y, Hanari N, Yusup G, et al. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol, 2011, 18(10):2946-2951. ［8］ Xiao Y, Teng Y, Zhang R, et al. Antitumor effect of the selective COX-2 inhibitor celecoxib on endometrial adenocarcinoma in vitro and in vivo. Oncol Lett, 2012, 4(6):1219-1224. ［9］ Che SM, Zhang XZ, Hou L, et al. Cyclooxygenase-2 inhibitor NS398 enhances radiosensitivity of radioresistant esophageal cancer cells by inhibiting AKT activation and inducing apoptosis. Cancer Invest, 2010, 28(7):679-688. ［10］ Omahen DA. Augmentation of chemotherapytriggered glioma cell apoptosis by blockade of arachidonic acid metabolismthe potential role of ceramide accumulation. Med Hypotheses, 2011, 77(5):726-733. ［11］ Duan DP, Dang XQ, Wang KZ, et al. The cyclooxygenase-2 inhibitor NS398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway. Oncol Rep, 2012, 28(5):1693-1700. ［12］孙权权, 袁亚维, 李刚, 等. shRNAmir慢病毒载体沉默COX-2对鼻咽癌细胞生长转移及放化疗敏感性的影响. 南方医科大学学报, 2011, 31(4):599-603. ［13］ Kang KB, Zhu C, Yong SK, et al. Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53dependent G1 cell cycle arrest and autophagy. Mol Cancer, 2009, 8:66. ［14］徐慧婷, 于世英, 翁丹卉, 等. RNA干扰抑制环氧化酶2表达对宫颈癌HeLa细胞增殖的影响. 华中科技大学学报, 2009, 38(1):59-63. ［15］ Li G, Xie B, Li X, et al. Downregulation of survivin and hypoxiainducible factor1α by βelemene enhances the radiosensitivity of lung adenocarcinoma xenograft. Cancer Biother Radiopharm, 2012, 27(1):56-64. ［16］ Liu J, Zhang J, Wang X. HIF-1 and NDRG2 contribute to hypoxiainduced radioresistance of cervical cancer Hela cells. Exp Cell Res, 2010, 316(12):1985-1993. ［17］ Semenza GL. Hypoxiainducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci, 2012, 33(4): 207-214. ［18］ Stasinopoulos I, O′Brien DR, Bhujwalla ZM. Inflammation, but not hypoxia,mediated HIF1alpha activation depends on COX-2. Cancer Biol Ther, 2009, 8(1):31-35. ［19］ Zhang YF, Ruan LH, Zhao XQ. Effects of COX-2 inhibitor celecoxib on expressions of VEGF, bFGF and TGFβ mRNA in acute leukemia cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2012,20(5):1086-1089. ［20］ Chen J, Ran Y, Hong C, et al. Anticancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expressing COX-2 oncoprotein. Cytotechnology, 2010, 62(5):431-438. ［21］ Markosvan N, Chen EP, Ndong VN, et al. Deletion of cyclooxygenase-2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors.Carcinogenesis, 2011, 32(10):1441-1449. ［22］ Hunter NR, Valdecanas D, Liao Z, et al. Mitigation and treatment of radiationinduced thoracic injury with a cyclooxygenase-2 inhibitor, Celecoxib. Int J Oncol Biol Phys, 2013, 85(2):472-476. ［23］ Khayyal MT, El Ghazaly MA, El Hazek RM, et al. The effects of celecoxib, a COX-2 selective inhibitor, on acute inflammation induced in irradiated rats. Inflammopharmacology, 2009, 17(5):255-266. ［24］ Yang HJ, Youn H, Seong KM, et al. Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation(IR)induced pulmonary inflammation. Biochem Pharmacol, 2011, 82(5):524-534. ［25］ Chai Y, Calaf GM, Zhou H, et al. Radiation induced COX-2 expression and mutagenesis at non targeted lung tissues of gpt delta transgenic mice. Br J Cancer, 2013, 108(1):91-98. ［26］ Hofer M, Pospisil M, Hoferova Z, et al. Stimulatory action of cyclooxygenase inhibitors on hematopoiesis:a Review. Molecules, 2012, 17(5):5615-5625.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.